Hostname: page-component-848d4c4894-4hhp2 Total loading time: 0 Render date: 2024-05-26T12:03:54.528Z Has data issue: false hasContentIssue false

Neurotrophics correlates and functional remediation in bipolar disorder. A pilot study

Published online by Cambridge University Press:  01 September 2022

V. Accardo*
Affiliation:
University of Brescia, Department Of Molecular And Translational Medicine, Brescia, Italy University of Brescia School of Medicine, Department Of Mental Health And Addiction Services, Asst Spedali Civili, Brescia, Italy., Brescia, Italy
S. Barlati
Affiliation:
University of Brescia School of Medicine, Department Of Mental Health And Addiction Services, Asst Spedali Civili, Brescia, Italy., Brescia, Italy University of Brescia, Department Of Clinical And Experimental Sciences, Brescia, Italy
A. Vita
Affiliation:
University of Brescia School of Medicine, Department Of Mental Health And Addiction Services, Asst Spedali Civili, Brescia, Italy., Brescia, Italy University of Brescia, Department Of Clinical And Experimental Sciences, Brescia, Italy
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Bipolar disorder (BD) is a complex mental disorder. Cognitive dysfunction represents a core feature, strongly related with patients’ functional outcome. Functional Remediation (FR), is an integrated neuropsychological and psychosocial rehabilitation treatment aimed at enhancing cognitive functions in order to achieve full functional recovery(Torrent et al., 2013). Evidence highlighted an association of neurotrophins and cognitive dysfunctions. Particularly, BDNF has been investigated a potential biomarker. Preliminary studies explored the effects induced through FR interventions on serum BDNF levels(Bonnin et al., 2019). Evidences suggest that high BDNF serum levels are related to good cognitive functioning(Mora et al., 2019). Results require further explorations. The present pilot study targets to identify the neurobiological correlates of response, investigating the potential neuroprotective role of the FR.

Objectives

Assess the effectiveness of FR in ameliorate cognitive deficits measured with BAC-A and psychosocial functioning with FAST, in modifying BDNF levels in a sample of euthymic patients with BD, compared to standard treatment.

Methods

Two arms(1:1)randomized, rater-blinded, controlled study of 30out-patients with BD-I and BD-II, according to DSM-5 criteria. Patients between 18 and 55 years in euthymic phase. Neurocognitive and clinical assessments, at the same times, serum assessment of BDNF levels will be performed.

All patients will be assessed at baseline(T0), at the end of treatment(T1) and at the 3-month follow-up(T2).

Results

After treatment, patients receiving FR show better cognitive and psychosocial performance than those receiving TAU.

Conclusions

Given the important role of neutrophins in the pathogenesis of BD, identifying BD-specific biomarkers would contribute to understand the underlying neuro-pathophysiological processes and to personalize treatments.

Disclosure

No significant relationships.

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.